Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × INDUSTRY × Lutetium-177 × Clear all

Phase

Phase 1 5 Phase 2 3 Phase 1/2 2 Phase EARLY_PHASE1 1 Phase 4 1 Phase 3 1

Status

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Oligometastatic Prostate Cancer (OMPC) 1

Interventions

Carboplatin 272 Paclitaxel 264 Cisplatin 216 Docetaxel 209 pembrolizumab 192 Gemcitabine 185 Pemetrexed 136 Rituximab 129 Capecitabine 127 Bevacizumab 120 Dexamethasone 104 Fluorouracil 99 Cyclophosphamide 91 Doxorubicin 90 Trastuzumab 85 Prednisone 85 Nivolumab 80 Oxaliplatin 76 atezolizumab 65 durvalumab 64 Leucovorin 60 Injections 60 Lenalidomide 57 130-nm albumin-bound paclitaxel 57 Irinotecan 49 Drug Therapy 48 Letrozole 46 Fulvestrant 46 Bortezomib 46 Bendamustine Hydrochloride 43

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05939414 2026-02-24

PSMA-DC

Novartis

Phase 3 Recruiting

Oligometastatic Prostate Cancer (OMPC)

Data powered by HemOnc (CC BY 4.0) Colophon ⚡